This inventor holds 2 USPTO granted patents and 2 published patent applications. Top assignees: Astex Therapeutics Limited, Cancer Research Technology Limited. Active years: 2023-2024.
Company Filing History:
2 out of 126 
2 out of 268 Years Active: 2023-2024
Title: The Innovations of Matthew James Gaunt
Introduction
Matthew James Gaunt is a notable inventor based in Cambridge, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of isoindolinone derivatives. With a total of two patents to his name, Gaunt's work has the potential to impact cancer treatment and related therapies.
Latest Patents
Gaunt's latest patents focus on isoindolinone inhibitors of the MDM2-P53 interaction. The inventions relate to processes for preparing isoindolin-1-one derivatives, specifically the compound (2S,3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1-(oxan-4-yl)propyl]-1-methoxy-3-oxo-2,3-dihydro-1H-isoindol-2-yl]-2-methylpropanoic acid. Additionally, the patents cover crystalline forms of this compound and its salts, showcasing the depth of his research and innovation.
Career Highlights
Throughout his career, Matthew James Gaunt has worked with prominent organizations such as Astex Therapeutics Limited and Cancer Research Technology Limited. His experience in these companies has allowed him to collaborate on groundbreaking research and development projects in the pharmaceutical industry.
Collaborations